Table 3. Association between clinical and pathological characteristics of study participants and survival and progression after 5-FU/oxaliplatin chemotherapy.

		Survival		Progressiona
Factors	No. of patients	Relative risk of dyingb and 95% CI	P-valuec	Relative risk of progressiona and 95% CI	P-valuec
Age (years)			0.70		0.54
>60	50	1		1
51–60	26	1.27 (0.69, 2.35)		1.03 (0.60, 1.77)
⩽50	30	1.16 (0.64, 2.08)		1.30 (0.79, 2.13)
Gender			0.72		0.50
Male	79	1		1
Female	27	1.10 (0.65, 1.87)		0.84 (0.51, 1.40)
Ethnicity			0.26		0.56
Caucasian	75	1		1
Hispanic	14	0.65 (0.30, 1.38)		1.00 (0.51, 1.97)
Black	6	0.46 (0.14, 1.47)		0.70 (0.25, 1.96)
Asian	11	0.55 (0.20, 1.52)		1.47 (0.75, 2.90)
Histology			0.058		0.69
Moderate/well	77	1		1
Poor	16	1.85 (0.93, 3.66)		1.13 (0.61, 2.11)
Unknown	13
Side of tumour			0.077		0.51
Left	71	1		1
Right	34	1.55 (0.93, 2.60)		1.16 (0.74, 1.82)
Unknown	1
Number of metastatic sites			0.95		0.60
1	46	1		1
2	41	0.94 (0.57, 1.63)		0.81 (0.51, 1.30)
3+	19	0.91 (0.46, 1.78)		0.79 (0.43, 1.47)
Performance status			<0.001		0.001
0–1	78	1		1
2	28	3.46 (1.99, 6.01)		2.15 (1.30, 3.57)

5-FU=5-fluorouracil; CI=confidence interval.

^aTime to progression was calculated from the time that patient started treatment until the patient was taken off study. If the relative risk is greater than 1, the relative risk can be thought as the average increased risk of progression at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.

^bIf the relative risk is greater than 1, the relative risk can be thought as the average increased risk of dying at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.

^cP-value based on log-rank test.